Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or me...
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
About this item
Full title
Author / Creator
Long, Georgina V, Prof , Dummer, Reinhard, Prof , Hamid, Omid, MD , Gajewski, Thomas F, Prof , Caglevic, Christian, MD , Dalle, Stephane, Prof , Arance, Ana, MD , Carlino, Matteo S, PhD , Grob, Jean-Jacques, Prof , Kim, Tae Min, Prof , Demidov, Lev, Prof , Robert, Caroline, Prof , Larkin, James, Prof , Anderson, James R, PhD , Maleski, Janet, BSN , Jones, Mark, MD , Diede, Scott J, MD and Mitchell, Tara C, MD
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
SummaryBackgroundImmunotherapy combination treatments can improve patient outcomes. Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising antitumour activity in the phase 1–2 ECHO-202/KEYNOTE-037 study in advanced melanoma. In this trial, we aimed to compare progression-free survival and overall survival in...
Alternative Titles
Full title
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Authors, Artists and Contributors
Author / Creator
Dummer, Reinhard, Prof
Hamid, Omid, MD
Gajewski, Thomas F, Prof
Caglevic, Christian, MD
Dalle, Stephane, Prof
Arance, Ana, MD
Carlino, Matteo S, PhD
Grob, Jean-Jacques, Prof
Kim, Tae Min, Prof
Demidov, Lev, Prof
Robert, Caroline, Prof
Larkin, James, Prof
Anderson, James R, PhD
Maleski, Janet, BSN
Jones, Mark, MD
Diede, Scott J, MD
Mitchell, Tara C, MD
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_hal_primary_oai_HAL_hal_04030780v1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_hal_primary_oai_HAL_hal_04030780v1
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(19)30274-8
